Insight

First response of a child with neuroblastoma and a BARD1 germline mutation to PARP inhibitors – NCI Center for Cancer Research

Photo taken from Eytan Ruppin/X

Aug 24, 2024, 18:10

First response of a child with neuroblastoma and a BARD1 germline mutation to PARP inhibitors – NCI Center for Cancer Research

NCI Center for Cancer Research shared on LinkedIn:

“NEW FINDINGS: A recent case study reported the first response of a child with neuroblastoma and a BARD1 germline mutation to PARP inhibitors. The study demonstrates potential for further studies into HRR deficiencies in pediatric cancer.

Read more about this work, which was published in The New England Journal of Medicine.

Eytan Ruppin, M.D., Ph.D., Chief of the Cancer Data Science Laboratory, was part of this research team. Dr. Ruppin utilizes multi-disciplinary algorithmic computationally driven analysis of large-scale biomedical omics and clinical data, with an emphasis on artificial intelligence and machine/deep learning approaches.”

NCI

Source: NCI Center for Cancer Research/LinkedIn

BARD1 germline cancer Cancer Data Science Laboratory Eytan Ruppin NCI Center for Cancer Research neuroblastoma OncoDaily Oncology PARP inhibitors The New England Journal of Medicine.

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

Special Coverage